23 Feb Talaris Therapeutics
Scott Requadt, CEO
Talaris Therapeutics is a late clinical-stage, publicly traded biotechnology company that is developing a one-time cell therapy that has the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant immune and metabolic disorders. In a Phase II clinical study in 37 living donor kidney transplant recipients, Talaris’ investigational therapy, FCR001, enabled 70% of kidney transplant recipients to become tolerized to their donated kidney, enabling them to durably discontinue all of their chronic immunosuppression without rejecting their kidney. All of these patients have remained off immunosuppression for the full duration of follow-up (median > 6 years, longest > 11 years). Talaris is currently enrolling FREEDOM-1, a pivotal Phase III clinical study of FCR001 in living donor kidney transplant recipients, and expects to initiate two additional Phase II studies of FCR001 before the end of 2021.